Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

Weitere Dokumente

N-912

Supelco

Norbuprenorphin -Lösung

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C25H35NO4
CAS-Nummer:
78715-23-8
Molekulargewicht:
413.55
EG-Nummer:
200-659-6
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

100 μg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

forensics and toxicology

Format

single component solution

Lagertemp.

−20°C

SMILES String

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChIKey

YOYLLRBMGQRFTN-IOMBULRVSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Norbuprenorphin ist der primäre aktive Metabolit des Opiats Buprenorphin im Urin. Diese zertifizierte Dotierlösung® eignet sich Ausgangsmaterial für die Kalibrierung oder Kontrolle in GC/MS- oder LC/MS-Anwendungen in der forensischen Analytik, klinischen Toxikologie, Urin-Drogenkontrolle oder Schmerzmittelüberwachung. Buprenorphin, das unter den Handelsnamen Buprenex®, Subutex® und Suboxone® verkauft wird, ist ein Opiat und wird für die Behandlung der Opiodabhängigkeit und die Behandlung mäßiger akuter Schmerzen verwendet.

Anwendung

  • Norbuprenorphine solution for opioid receptor research: A study analyzed the pharmacokinetics of buprenorphine and its metabolite norbuprenorphine in neutered male cats anesthetized with isoflurane, highlighting its role in opioid receptor agonist research and the impact on pain management strategies (Pypendop et al., 2023).
  • Metabolite solution for biochemistry experiments: A study addressed the quantitative analysis of buprenorphine and norbuprenorphine levels in urine, demonstrating norbuprenorphine′s application in biochemistry experiments to understand opioid use disorder and its treatment (Holt et al., 2018).

Rechtliche Hinweise

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

B-035

Buprenorphin-Glucuronid -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

Buprenorphin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphin-D4 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-902

Buprenorphin -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphin-D4 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Glucuronid-Norbuprenorphin -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphin -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphin-D3 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphin-D3 -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Marta Concheiro et al.
Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)
Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant
Hong K Kim et al.
Pediatrics, 130(6), e1700-e1703 (2012-11-07)
Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use
Giuseppe Lippi et al.
Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory
Tor Seldén et al.
Forensic science international, 220(1-3), 284-290 (2012-05-09)
Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.